Lapatinib Ditosylate and Rituximab and hyaluronidase human, recombinant Subcutaneous

• Generic Name: lapatinib
• Dosage Forms: n.a.
• Other Brand Names: Tykerb

In combination with letrozole for treatment of hormone receptor-positive metastatic breast cancer that overexpresses the human epidermal receptor type 2 (HER2) protein in postmenopausal women who are candidates for hormonal therapy. Combined therapy with lapatinib and an aromatase inhibitor has not been compared with trastuzumab-containing chemotherapy for treatment of metastatic breast cancer.

In combination with capecitabine for treatment of advanced or metastatic breast cancer in patients whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.

• Generic Name: hyaluronidase / rituximab
• Dosage Forms: n.a.
• Other Brand Names: Rituxan Hycela

Rituximab and hyaluronidase human, recombinant combination injection is used alone or together with other cancer medicines to treat follicular lymphoma and chronic lymphocytic leukemia (CLL). It is also used together with other medicines to treat diffuse large B-cell lymphoma (DLBCL) in people who have not received previous treatment.

Rituximab and hyaluronidase human, recombinant combination injection is an antineoplastic agent (cancer medicine). It interferes with the growth of cancer cells, which are eventually destroyed by the body.

Rituximab and hyaluronidase human, recombinant is to be given only by or under the direct supervision of your doctor.